Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

Open access
Zhou, Jingying, Liu, Man, Sun, Hanyong, Feng, Yu, Xu, Liangliang, Chan, Anthony W H, Tong, Joanna H, Wong, John, Chong, Charing Ching Ning, Lai, Paul B S, Wang, Hector Kwong-Sang, Tsang, Shun-Wa, Goodwin, Tyler, Liu, Rihe, Huang, Leaf, Chen, Zhiwei, Sung, Joseph JY, Chow, King Lau, To, Ka Fai, Cheng, Alfred Sze-Lok·2018·Gut

Abstract

Objective: Myeloid-derived suppressor cells (MDSCs) contribute to tumour immunosuppressive microenvironment and immune-checkpoint blockade resistance. Emerging evidence highlights the pivotal functions of cyclin-dependent kinases (CDKs) in tumour immunity. Here we elucidated the role of tumour-intrinsic CDK20, or cell cycle-related kinase (CCRK) on immunosuppression in hepatocellular carcinoma (HCC). Design: Immunosuppression of MDSCs derived from patients with HCC and relationship with CCRK were determined by flow cytometry, expression analyses and co-culture systems. Mechanistic studies were also conducted in liver-specific CCRK -inducible transgenic (TG) mice and Hepa1–6 orthotopic HCC models using CRISPR/Cas9-mediated Ccrk depletion and liver-targeted nanoparticles for interleukin (IL) 6 trapping. Tumorigenicity and immunophenotype were assessed on single or combined antiprogrammed death-1-ligand 1 (PD-L1) therapy. Results: Tumour-infiltrating CD11b + CD33 + HLA-DR − MDSCs from patients with HCC potently inhibited autologous CD8 + T cell proliferation. Concordant overexpression of CCRK and MDSC markers (CD11b/CD33) positively correlated with poorer survival rates. Hepatocellular CCRK stimulated immunosuppressive CD11b + CD33 + HLA-DR − MDSC expansion from human peripheral blood mononuclear cells through upregulating IL-6. Mechanistically, CCRK activated nuclear factor-κB (NF-κB) via enhancer of zeste homolog 2 (EZH2) and facilitated NF-κB-EZH2 co-binding to IL-6 promoter. Hepatic CCRK induction in TG mice activated the EZH2/NF-κB/IL-6 cascade, leading to accumulation of polymorphonuclear (PMN) MDSCs with potent T cell suppressive activity. In contrast, inhibiting tumorous Ccrk or hepatic IL-6 increased interferon γ + tumour necrosis factor-α + CD8 + T cell infiltration and impaired tumorigenicity, which was rescued by restoring PMN-MDSCs. Notably, tumorous Ccrk depletion upregulated PD-L1 expression and increased intratumorous CD8 + T cells, thus enhancing PD-L1 blockade efficacy to eradicate HCC. Conclusion: Our results delineate an immunosuppressive mechanism of the hepatoma-intrinsic CCRK signalling and highlight an overexpressed kinase target whose inhibition might empower HCC immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-314032

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 201

Metadata

Authors
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., Wang, H. K.-S., Tsang, S.-W., Goodwin, T., Liu, R., Huang, L., Chen, Z., Sung, J. J., Chow, K. L., To, K. F., & Cheng, A. S.-L.
Venue
Gut
Publisher
BMJ
Published
2017-09-22
Volume
67
Issue
5
Pages
931-944
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2758825393
Cited by
201
References
10
FWCI
5.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. https://app.cochat.ai/papers/10.1136/gutjnl-2017-314032
The paper
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., Wang, H. K.-S., Tsang, S.-W., Goodwin, T., Liu, R., Huang, L., Chen, Z., Sung, J. J., Chow, K. L., To, K. F., & Cheng, A. S.-L. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. https://doi.org/10.1136/gutjnl-2017-314032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.